Product Description: Vorolanib (CM082) is an orally active, potent multikinase VEGFR/PDGFR inhibitor. Vorolanib is a potent ATP-binding cassette (ABC) transporter inhibitor. Vorolanib is an angiogenesis inhibitor and has antitumor activity combined with ZD1839 (HY-50895)[1][2].
Applications: Neuroscience-Neuromodulation
Formula: C23H26FN5O3
References: [1]Lejia Xu, et al. CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2. Mol Ther Oncolytics. 2019 Dec 27;16:100-110./[2]Kun Zhang, et al. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of ZD1839 on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo. Thorac Cancer. 2020 Jun;11(6):1566-1577.
CAS Number: 1013920-15-4
Molecular Weight: 439.48
Compound Purity: 99.88
Research Area: Cancer; Cardiovascular Disease
Solubility: DMSO : 27 mg/mL (ultrasonic)
Target: PDGFR;VEGFR
English
Deutsch
